Marc Raab, MD, PhD, discussed the MajesTEC-5 trial of teclistamab plus standard myeloma therapies in transplant-eligible newly diagnosed multiple myeloma.

For decades, the diagnosis of multiple myeloma required evidence of end-organ damage characterized by myeloma-defining events ...

A large U.S. registry study of ide-cel CAR-T therapy in relapsed/refractory multiple myeloma shows strong response rates and a safety profile comparable to clinical trials—even among older and ...

During a live event, Patrick Moore, MD, discussed the KarMMa-3 subgroup analyses and quality of life for patients with ...

Hematologist-oncologist Mateo Mejia Saldarriaga, MD, combines clinical care with research aimed at helping patients with ...

"We are really pleased to have our abstract accepted by ASCO, it indicates the novelty and importance of our TeloView® based MRD applications and the impact we hope to have on patients and physicians ...

New research suggested the monoclonal antibody may help ward off progression to myeloma or death. Medscape Medical News, December 16, 2024 ASH 2024 MM: Dexamethasone-Sparing Approach Helps Frail ...

The addition of subcutaneous daratumumab to triplet therapy improved outcomes for certain patients with newly diagnosed ...

CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, ...

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved an indication extension of DARZALEX® (daratumumab) subcutaneous (SC) ...